Results 251 to 260 of about 266,614 (380)

A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson's disease. [PDF]

Alzheimers Dement (N Y)
Ahammad RU, Spencer B, Quach B, Salehi S, Rissman RA.   +4 more
europepmc   +1 more source

Site‐specific m6A‐miR‐494‐3p, not unmethylated miR‐494‐3p, compromises blood brain barrier by targeting tight junction protein 1 in intracranial atherosclerosis

British Journal of Pharmacology, EarlyView.
Background and Purpose Intracranial atherosclerosis is one of the most common causes of ischaemic stroke. However, there is a substantial knowledge gap on the development of intracranial atherosclerosis. Intracranial arteries are characterized by an upregulation of tight junctions between endothelial cells, which control endothelial permeability.
Tamar Woudenberg, M. Leontien van der Bent, Veerle Kremer, Ingeborg S. E. Waas, Mat J. A. P. Daemen, Reinier A. Boon, Paul H. A. Quax, A. Yaël Nossent   +7 more
wiley   +1 more source

Polarity Gene PARD6B Promotes Tumor Growth of Colorectal Cancer via Increasing MYC Expression

Cancer Science, EarlyView.
Partitioning Defective 6B (PARD6B), a polarity gene, functions as a scaffold node for the Par protein complex. In this study, we showed that highly expressed PARD6B could promote CRC growth by upregulating MYC expression while suppressing miR‐34c expression.
Kosuke Hirose, Takaaki Masuda, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Yusuke Nakano, Masahiro Hashimoto, Takanari Tatsumi, Tomohiko Ikehara, Takashi Ofuchi, Shinsaku Itoyama, Yuki Ando, Yasuo Tsuda, Yusuke Yonemura, Keishi Sugimachi, Eiji Oki, Tomoharu Yoshizumi, Koshi Mimori   +18 more
wiley   +1 more source

Repeat length as a key determinant for disease severity and antisense oligonucleotide activity in myotonic dystrophy type 1. [PDF]

Mol Ther Methods Clin Dev
El Boujnouni N, Ripken L, Willemse M, van der Sanden B, Neveling K, Hoischen A, Brock R, Wansink DG.   +7 more
europepmc   +1 more source

Potent and nontoxic antisense oligonucleotides containing locked nucleic acids [PDF]

, 2000
Claes Wahlestedt, Peter Salmi, Liam Good, Johanna Kela, Thomas Johnsson, Tomas Hökfelt, Christian Broberger, Frank Porreca, Josephine Lai, Kunkun Ren, Michael H. Ossipov, Alexei A. Koshkin, Nana Jakobsen, Jan Skouv, Henrik Oerum, Mogens Havsteen Jacobsen, Jesper Wengel   +16 more
openalex   +1 more source

IMPROVE 2023: The 2nd International Meeting on Pathway‐Related Obesity: Vision & Evidence

Clinical Obesity, EarlyView.
ABSTRACT A total of 150 clinicians and researchers representing 19 countries came together in person and online to participate in the highly anticipated 2nd International Meeting on Pathway‐Related Obesity: Vision & Evidence (IMPROVE), held on 13–15 December 2023 in Paris, France.
Karine Clément, Erica L. T. van den Akker, Jesús Argente, Phil Beales, Metin Cetiner, Béatrice Dubern, Sadaf Farooqi, Aurélie Gouronc, Peter Kühnen, Johanne Le Beyec, Louis Lebreton, David Meeker, Hermann L. Müller, Jean Muller, Christine Poitou, Patrick Sleiman, Christian Vaisse, Martin Wabitsch, Jacques Young, Hélène Dollfus   +19 more
wiley   +1 more source

Customized antisense oligonucleotide-based therapy for neurofilament-associated Charcot-Marie-Tooth disease. [PDF]

Brain
Medina J, Rebelo A, Danzi MC, Jacobs EH, Xu IRL, Ahrens KP, Chen S, Raposo J, Yanick C, Zuchner S, Saporta MA.   +10 more
europepmc   +1 more source

Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A [PDF]

, 2000
Fortunato Ciardiello, Rosa Caputo, G Pomatico, Michelino De Laurentiis, Sabino De Placido, Angelo Raffaele Bianco, Giampaolo Tortora   +6 more
openalex   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy. [PDF]

J Muscle Res Cell Motil
Chwalenia K, Wood MJA, Roberts TC.
europepmc   +1 more source